Inovio Pharmaceuticals, Inc.

What they do

INOVIO develops DNA medicines for HPV-related diseases, cancer, and infectious diseases, delivered using its proprietary CELLECTRA electroporation device, making its candidates drug-device combination products. Its lead candidate, INO-3107, is under FDA review for adults with recurrent respiratory papillomatosis (RRP) with a PDUFA target date of October 30, 2026. VGX-3100 for cervical dysplasia is being developed in Greater China by partner ApolloBio, and earlier-stage DNA-Encoded Monoclonal Antibody and DNA-Encoded Protein programs are in preclinical work. The company has no in-house sales team and is preparing launch through third parties.

Revenue drivers

• Grant and collaboration revenue — Revenue has fallen sharply for four straight years—from $1.8M in 2021 to $10.3M in 2022, $832,010 in 2023, $217,756 in 2024, and $65,343 in 2025—reflecting limited grant and collaboration activity; the company has no approved product sales.
• INO-3107 (RRP) — potential future product revenue — The lead candidate is under FDA review with an October 30, 2026 PDUFA date; if approved, INOVIO would depend on a contracted commercial organization because it has no in-house sales team, and it reports no current product revenue.
• VGX-3100 (cervical dysplasia) — partner-led — ApolloBio, INOVIO's partner in Greater China, reported positive topline Phase 3 results in May 2026 and plans to use them to support a future regulatory filing in China; INOVIO itself reports no revenue from this program.
• Government grants and collaboration agreements — The 10-K describes agreements with government agencies that are subject to termination and uncertain future funding, and notes that losing collaborators or partners would hurt development and potential profitability.

Recent performance

Revenue was $65,343 in 2025, down from $217,756 in 2024, $832,010 in 2023, $10.3M in 2022, and $1.8M in 2021. The company reported zero revenue in each of the last four quarters (2025-09-30 through 2026-06-30). Net loss narrowed to $85.0M in 2025 from $107.0M in 2024 and $135.0M in 2023, with diluted EPS of -$1.81 in 2025 versus -$3.95 in 2024. Operating cash flow was -$88.6M in 2025, an improvement from -$104.1M in 2024. At June 30, 2026, total assets were $49.4M, total liabilities $45.0M, shareholder equity $4.4M, and cash and equivalents $31.5M.

Strategy

INOVIO is focused on securing FDA approval of INO-3107 for RRP and is preparing commercial launch activities in anticipation of a 2026 approval. It engaged Syneos Health to recruit and deploy Medical Science Liaisons and to serve as contract sales organization in the U.S., and has engaged or identified a third-party logistics provider, Agency of Record, specialty distributor, specialty pharmacy, and patient hub. The company is also advancing next-generation DNA-Encoded Monoclonal Antibody and DNA-Encoded Protein programs, presenting preclinical Factor VIII data for Hemophilia A, and pursuing potential partners. Because it does not have sufficient working capital for the next twelve months, it states it will need strategic alliance and licensing arrangements, grant agreements, and/or public or private debt or equity financings, including At-the-Market offerings.

Risks

• Going concern / liquidity — The 10-K states INOVIO does not have sufficient working capital to fund planned operations for the next twelve months and substantial doubt exists about its ability to continue as a going concern, with an accumulated deficit of $1.8 billion at December 31, 2025.
• Accelerated approval eligibility for INO-3107 — The FDA's file acceptance letter noted a preliminary conclusion that INOVIO had not provided adequate information to justify accelerated approval eligibility, and the 10-Q says INOVIO is not currently planning to seek approval under the traditional pathway, which could require a Phase 3 trial at substantial cost.
• Drug-device combination and CELLECTRA dependence — Product candidates require marketing authorization for the CELLECTRA electroporation delivery device; without it, INOVIO cannot bring to market the DNA medicines that rely on that device.
• Commercial execution and competition — INOVIO has a small commercial organization and no in-house sales team, and the 10-Q cites competitive steps such as full approval of PAPZIMEOS for RRP as potentially impeding development and commercialization of its DNA medicines.

Outlook

Management says the FDA review of the INO-3107 BLA is advancing toward a PDUFA target action date of October 30, 2026, with a late-cycle review meeting and all scheduled pre-licensure inspections completed. At an informal clinical meeting the FDA did not discuss its preliminary comment on accelerated approval eligibility and said feedback on confirmatory trial design would be forthcoming. INOVIO states that current cash, cash equivalents, and short-term investments are anticipated to fund operations into late first quarter 2027, described as through a potential launch of INO-3107 if approved.